financetom
Business
financetom
/
Business
/
Tim Draper leads $2.5 mln funding round for crypto startup Ark Labs
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Tim Draper leads $2.5 mln funding round for crypto startup Ark Labs
Aug 25, 2024 4:49 AM

Aug 22 (Reuters) - Ark Labs, a three-month old startup

developing solutions to speed up bitcoin transactions and lower

costs, has raised $2.5 million in a pre-seed funding round led

by billionaire investor Tim Draper.

Besides venture capital firm Draper Associates, Fulgur

Ventures, Axiom Capital and angel investor Stephen Cole also

participated in the round, the startup said on Thursday.

WHY IT'S IMPORTANT

The funding underscores Silicon Valley's growing interest in

the companies seeking to make crypto, particularly bitcoin, a

mainstream mode of payment.

The world's biggest cryptocurrency has grown into a

formidable asset class, with billions of dollars in inflows from

traders, particularly after exchange-traded funds tracking its

price were approved in January.

However, some analysts say bitcoin will need to have more

utility to sustain its high level of interest.

Ark said it will use the funds to expand its team and

enhance its technology.

CONTEXT

Draper, who founded Draper Associates in 1985, has also

invested in SpaceX, Tesla, Coinbase and

Robinhood.

He also led a funding round in bitcoin lending company Zest

Protocol in May.

KEY QUOTES

"Today, we have to focus not only on how to buy and store

bitcoin but how to use it as a medium of exchange for everyday

purposes," Draper said.

Ark allows for "seamless bitcoin payments," he added.

"Bitcoin adoption faces a strong headwind until any

non-technical person can safely achieve exposure," said Henry

Robinson, co-founder of crypto mining firm Decimal Digital

Currency.

"As mature investors and mature capital with longer

timeframes grow their positions in bitcoin, the asset class will

mature and their approach will trickle down to individual asset

and fund managers."

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved